Phil Green, PhD Consultant

Extensive experience in the pharmaceutical industry in the commercialization of drug delivery products. Phil has a specific focus on commercial aspects of combination drug-devices and IV to SC switching.

From 2009 to 2018 Phil was Executive Director, Biologics Device Strategy at Merck US. In this role he was responsible for formulating commercial strategies around several biosimilar and oncology device-based combination products including leading marketing efforts for a new subcutaneous Keytruda formulation.

Previously, Phil worked for 16 years with Becton-Dickinson where he was responsible for creating partnerships with Pharma Co’s for Advanced Delivery Technology including intradermal delivery systems, patch pumps and other injection devices. Before joining Becton-Dickinson he held multiple drug delivery roles with Novartis (Zyma) and L’Oreal/Galderma.

Phil received his BSc in Chemistry from Bristol University, UK, a doctorate degree in Pharmaceutical Chemistry from School of Pharmacy Dept, Cardiff University, UK and post doctorate training at University of California, San Francisco.